NEW YORK, Nov. 13 – Visible Genetics of Toronto said Tuesday third-quarter revenues slipped slightly to $2.9 million, from $3.0 million in the year ago quarter, as product and service sales both fell.

On a positive note, Visible Genetics said that the US Food and Drug Administration had approved the company’s Trugene HIV-1 genotyping test for use in the clinical diagnostics market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.